Lodge et al.

**Supplementary File 1**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Embryonic** | | **Postnatal** | |
| **Genotype** | **Observed** | **Expected** | **Observed** | **Expected** |
| *Hesx1+/+;Yapfl/fl;Taz+/+* | 4  (13.3%) | 3-4  (12.5%) | 14  (13.1%) | 13-14  (12.5%) |
| *Hesx1+/+;Yapfl/fl;Taz+/-* | 7  (23.3%) | 7-8  (25%) | 35  (32.7%) | 26-27  (25%) |
| *Hesx1+/+;Yapfl/fl;Taz-/-* | 2  (6.7%) | 3-4  (12.5%) | 4  (3.7%) | 13-14  (12.5%) |
| *Hesx1Cre/+;Yapfl/fl;Taz+/+* | 1  (3.3%) | 3-4  (12.5%) | 15  (14.0%) | 13-14  (12.5%) |
| *Hesx1Cre/+;Yapfl/fl;Taz+/-* | 12  (40%) | 7-8  (25%) | 37  (34.6%) | 26-27  (25%) |
| *Hesx1Cre/+;Yapfl/fl;Taz-/-* | 4  (13.3%) | 3-4  (12.5%) | 2  (1.9%) | 13-14  (12.5%) |
| **Total** | 30 | | 107 | |